Background: The effects of chronic renal disease on society are significant. As the most widely employed renal replacement therapy ( RRT), hemodialysis generally requires vascular access (VA) to supply the 300–500 mL/min of blood flow necessary for efficient and adequate management. The current gold standard for obtaining a reliable as well as safe VA for Hemodialysis (HD) management is the development of a native Arteriovenous Fistula (AVF). We planned this study to identify the main causes of native A-V fistula maturation failure. Utilizing PubMed, Medscape, and other Medline databases to examine the success rate of arterial-venous fistula development till 2023. Each study that was considered for inclusion was reviewed separately. Those that met the following standards were considered for inclusion: Written in English, published in scholarly journals, and addressing both the early and late causes of failure in a native arterial-venous fistula. Research was simply ignored if it did not meet the predetermined standards. Ethical approval, eligibility requirements, controls, data completeness, and the clarity of assessment measures were all considered in this process. Our concerned study outcomes were gathered by independently abstracting information by utilizing a data collection form from each relevant study.

Conclusion: Most patients had a functioning fistula within 6 weeks of creation. However, a significant proportion of patients experienced complications such as thrombosis, hematoma, and pseudoaneurysm, which can contribute to early or late fistula failure